Specialty Pharmacy

Research reveals potential drug targets for cervical cancer associated with human papillomavirus.

New data reveals only a portion of hepatitis C positive individuals receive treatment.

Bioethicist calls attention to urgent need for HIV treatment efforts in pregnant women worldwide.

Delivery method may improve treatment for patients with Neimann Pick Type C1 disease.

Response times found to be 10% slower in people with Crohn’s disease than those without the disease.

Top news of the week in oncology, and cancer drug development.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.

Transmission rates reduced 96% among couples who both received treatment.

Novel drug is a bispecific T cell engager (BiTE) that targets the B-cell maturation antigen in multiple myeloma.

Underlying mechanisms of skin cancer reveal potential avenue to cure melanoma.

Expanded use of bundled payments in cancer for services such as mammography.

National Institutes of Health awards $9.4 million to improve HIV health care.

Top articles of the week on Specialty Pharmacy Times.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies can optimize the prior authorization process.

Pharmacy benefit manager alliance with retail pharmacy giant Walgreens is the first of its kind.

Researchers reveal how anti-HIV inhibitors bind to the wrong target.

Praluent lowers LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH).

CRISPR-Cas9 stabilizes the guide RNA in live cells.

Combinations with hypoxia-activated prodrugs may eliminate non-small cell lung cancer tumors.

Top news of the day from across the healthcare landscape.

Omega-3 fatty acid supplements may help address the growing prevalence of type 2 diabetes mellitus and diabetic retinopathy.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can best utilize data to improve patient outcomes.

Erelzi, an etanercept biosimilar, was approved for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

Pharmacokinetics of tecarfarin were not compromised by renal function like it was with warfarin.

The toxicity of cancer drugs increasingly causing cardiovascular complications in patients.

Top news of the day from across the health care landscape.

Researchers seek to reduce the significant HIV risk among homeless people.

Research advances work towards targeted therapies for type 2 diabetes.